Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 23, 2026, 8:45 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 187 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Psilocybin Clear all
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers

A Study of a Psilocybin Analog (CYB003) in Healthy Participants With and Without Major Depressive Disorder

NCT05385783
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
CYB003, Psychotherapy, Placebo, Psychological Support
Drug · Behavioral
Lead sponsor
Cybin IRL Limited
Industry
Eligibility
21 Years to 65 Years
Enrollment
57 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
3
States / cities
Atlanta, Georgia • Decatur, Georgia • Eatontown, New Jersey
Source: ClinicalTrials.gov public record
Updated Mar 25, 2024 · Synced Oct 23, 2026, 8:45 AM EDT
Completed Phase 3 Interventional

Efficacy, Safety, and Tolerability of COMP360 in Participants With TRD

NCT05624268
View directory record Official record
Conditions
Treatment Resistant Depression
Interventions
Psilocybin
Drug
Lead sponsor
COMPASS Pathways
Industry
Eligibility
18 Years and older
Enrollment
258 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
40
States / cities
Tuscon, Arizona • Culver City, California • Garden Grove, California + 30 more
Source: ClinicalTrials.gov public record
Updated Aug 10, 2026 · Synced Oct 23, 2026, 8:45 AM EDT
Active, not recruiting Phase 3 Interventional

Psilocybin-Assisted Therapy in Treatment-Resistant Depression

NCT06303739
View directory record Official record
Conditions
Refractory Depression, Treatment Resistant Depression
Interventions
psilocybin
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 70 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated May 6, 2026 · Synced Oct 23, 2026, 8:45 AM EDT
Recruiting Phase 2 Interventional

TRIPS - Treatment to Improve Depression and/or Anxiety Using Psilocybin-assisted Psychotherapy in Cancer Survivors

NCT06801041
View directory record Official record
Conditions
Depression, Anxiety, Cancer
Interventions
Psilocybin
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 12, 2026 · Synced Oct 23, 2026, 8:45 AM EDT
Completed Early Phase 1 Interventional Results available

Psilocybin Cancer Anxiety Study

NCT00957359
View directory record Official record
Conditions
Cancer
Interventions
Psilocybin, Niacin
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 76 Years
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2018
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 20, 2020 · Synced Oct 23, 2026, 8:45 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Pilot Study: Effects of Psilocybin on Behavior, Psychology and Brain Function in Long-term Meditators

NCT01988311
View directory record Official record
Conditions
Psilocybin, Hallucinogens, Pharmacologic Actions, Central Nervous System Agents, Therapeutic Uses, Psychotropic Drugs
Interventions
psilocybin
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
25 Years to 80 Years
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated May 20, 2014 · Synced Oct 23, 2026, 8:45 AM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

The ENHANCE Study: taVNS and Psilocybin

NCT05866471
View directory record Official record
Conditions
Healthy, Psychedelic Experiences, Vagus Nerve Stimulation
Interventions
Psilocybin, Transcutaneous auricular Vagus Nerve Stimulation (taVNS), Psychosocial Support Alone, Sham taVNS
Drug · Device · Behavioral + 1 more
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years to 70 Years
Enrollment
115 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2028
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Oct 20, 2026 · Synced Oct 23, 2026, 8:45 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional

Psilocybin Therapy for Chronic Low Back Pain

NCT05351541
View directory record Official record
Conditions
Chronic Low-back Pain
Interventions
Psilocybin therapy with Zolpidem and Modafinil, Psilocybin therapy with Zolpidem, Psilocybin therapy with Modafinil, Psilocybin therapy with Placebo
Drug
Lead sponsor
Joshua Woolley, MD, PhD
Other
Eligibility
25 Years to 70 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Apr 29, 2026 · Synced Oct 23, 2026, 8:45 AM EDT
Recruiting Phase 1 Interventional

Adjunctive Effects of Psilocybin and a Formulation of Buprenorphine

NCT04161066
View directory record Official record
Conditions
Opioid Use Disorder
Interventions
Psilocybin with facilitated counseling
Drug
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
21 Years to 65 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jul 7, 2026 · Synced Oct 23, 2026, 8:45 AM EDT
Active, not recruiting Phase 3 Interventional

Efficacy, Safety, and Tolerability of Two Administrations of COMP360 in Participants With TRD

NCT05711940
View directory record Official record
Conditions
Treatment Resistant Depression
Interventions
Psilocybin
Drug
Lead sponsor
COMPASS Pathways
Industry
Eligibility
18 Years and older
Enrollment
572 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
62
States / cities
Gilbert, Arizona • Bellflower, California • Encino, California + 50 more
Source: ClinicalTrials.gov public record
Updated Aug 10, 2026 · Synced Oct 23, 2026, 8:45 AM EDT
Active, not recruiting Phase 2 Interventional

Pilot Trial of Visual Healing® in Psilocybin-assisted Therapy for Alcohol Use Disorder

NCT04410913
View directory record Official record
Conditions
Alcohol Use Disorder
Interventions
Psilocybin plus Visual Healing Set and Setting, Psilocybin plus Standard Set and Setting
Drug
Lead sponsor
Keith Heinzerling
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Santa Monica, California
Source: ClinicalTrials.gov public record
Updated Jan 17, 2023 · Synced Oct 23, 2026, 8:45 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety for Home Administration of Microdose Psilocybin Use

NCT06450210
View directory record Official record
Conditions
Psychedelic Experiences
Interventions
psilocybin trihydrate, Placebo
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
21 Years to 60 Years
Enrollment
17 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2026
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 14, 2026 · Synced Oct 23, 2026, 8:45 AM EDT
Recruiting Phase 1 Interventional

Psilocybin as a Novel Therapy for Residual Anhedonia

NCT07607938
View directory record Official record
Conditions
Anhedonia, Emotional Blunting
Interventions
Psilocybin, Placebo
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 65 Years
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 15, 2026 · Synced Oct 23, 2026, 8:45 AM EDT
Withdrawn Phase 2 Interventional

Inpatient Buprenorphine Induction With Psilocybin for Opioid Use Disorder

NCT06005662
View directory record Official record
Conditions
Opioid Use Disorder
Interventions
Psilocybin
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
21 Years to 70 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027 – 2028
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 23, 2026 · Synced Oct 23, 2026, 8:45 AM EDT
Active, not recruiting Phase 2 Interventional

PsiloStudy: Psilocybin With Psychological Support (Psi-PS) for Military Veterans and First Responders With Co-occurring PTSD & Alcohol Use Disorder (AUD)

NCT06853912
View directory record Official record
Conditions
Alcohol Use Disorder (AUD), PTSD
Interventions
Psilocybin 25 mg, Maltodextrin (Placebo)
Drug
Lead sponsor
Nathan Brashares Sackett
Other
Eligibility
21 Years to 65 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Aug 13, 2026 · Synced Oct 23, 2026, 8:45 AM EDT
Completed Phase 2 Interventional Results available

Effects and Therapeutic Potential of Psilocybin in Alcohol Dependence

NCT01534494
View directory record Official record
Conditions
Alcohol Dependence
Interventions
Psilocybin
Drug
Lead sponsor
University of New Mexico
Other
Eligibility
25 Years to 65 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Albuquerque, New Mexico
Source: ClinicalTrials.gov public record
Updated Sep 26, 2023 · Synced Oct 23, 2026, 8:45 AM EDT
Recruiting Phase 2 Interventional

Psilocybin-Assisted Therapy

NCT07332143
View directory record Official record
Conditions
PTSD
Interventions
psilocybin, Supportive Therapy, Prolonged Exposure Therapy
Drug · Behavioral
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Oct 1, 2026 · Synced Oct 23, 2026, 8:45 AM EDT
Withdrawn Phase 2 Interventional

Psilocybin-Assisted Psychotherapy for Anxiety in People With Stage IV Melanoma

NCT00979693
View directory record Official record
Conditions
Anxiety, Stage IV Melanoma
Interventions
psilocybin
Drug
Lead sponsor
Multidisciplinary Association for Psychedelic Studies
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
Miami Beach, Florida
Source: ClinicalTrials.gov public record
Updated Dec 26, 2023 · Synced Oct 23, 2026, 8:45 AM EDT
Completed Phase 1 Interventional

Psilocybin for the Treatment of Migraine Headache

NCT03341689
View directory record Official record
Conditions
Migraine Headache
Interventions
High Dose Psilocybin, Low Dose Psilocybin, Placebo
Drug
Lead sponsor
Yale University
Other
Eligibility
21 Years to 65 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1
States / cities
West Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Oct 12, 2023 · Synced Oct 23, 2026, 8:45 AM EDT
Completed Phase 2 Interventional

Evaluation of Psilocybin in Anorexia Nervosa: Safety and Efficacy

NCT04661514
View directory record Official record
Conditions
Anorexia Nervosa
Interventions
Psilocybin
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years to 40 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Jul 25, 2022 · Synced Oct 23, 2026, 8:45 AM EDT
Completed Phase 1 Interventional

Effects of Psilocybin in Anorexia Nervosa

NCT04052568
View directory record Official record
Conditions
Anorexia Nervosa
Interventions
Psilocybin
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 65 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated May 6, 2023 · Synced Oct 23, 2026, 8:45 AM EDT
Recruiting Phase 1 Interventional

Psychedelic Healing: Adjunct Therapy Harnessing Opened Malleability

NCT07053917
View directory record Official record
Conditions
Stroke, Chronic Stroke, Intracerebral Haemorrhage, Intracerebral Haemorrhage (ICH), Intracerebral Hemorrhage Basal Ganglia, Ischemic Stroke, Ischemic Stroke and Hemorrhagic Stroke, Hemiparesis After Stroke, Hemiplegia Following Ischemic Stroke, Hemiplegia and Hemiparesis, Hemiplegia and/or Hemiparesis Following Stroke, Middle Cerebral Artery Stroke
Interventions
Psilocybin (Usona Institute)
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 13, 2026 · Synced Oct 23, 2026, 8:45 AM EDT
Recruiting Phase 2 Interventional

Wellcome Leap Psilocybin for OUD

NCT06786325
View directory record Official record
Conditions
Opioid Use Disorder
Interventions
Psilocybin
Drug
Lead sponsor
Anna Rose Childress, Ph.D.
Other
Eligibility
18 Years to 60 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 29, 2025 · Synced Oct 23, 2026, 8:45 AM EDT
Not yet recruiting Phase 2 Interventional Accepts healthy volunteers

Psilocybin-Assisted Physical Therapy in Chronic Low Back Pain

NCT07306364
View directory record Official record
Conditions
Chronic Low Back Pain (CLBP), Physical Therapy, Psilocybin
Interventions
Psilocybin 10 mg, Psilocybin 25 mg, Niacin 100 mg
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years to 65 Years
Enrollment
45 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2029
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Aug 19, 2026 · Synced Oct 23, 2026, 8:45 AM EDT